UBS AM
CRVS icon

UBS AM’s Corvus Pharmaceuticals CRVS Stock Holding History

UBS AM’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
74,369
+68,253
+1,116% +$947K ﹤0.01% 2309
2026
Q1 		$89.5K Buy
6,116
+5,391
+744% +$86K ﹤0.01% 2859
2025
Q4 		$5.58K Buy
+725
New +$5.72K ﹤0.01% 2964

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

UBS AM's CRVS Position: Q2 2026 in Review

UBS AM increased its Corvus Pharmaceuticals (CRVS) stake by 1,116% in Q2 2026, buying an estimated $947K and bringing the position to 74,369 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2309.

UBS AM first reported a position in CRVS in Q4 2025 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • UBS AM held 74,369 shares of Corvus Pharmaceuticals worth $1.11M as of Q2 2026.
  • UBS AM bought 68,253 Corvus Pharmaceuticals shares in Q2 2026, an estimated $947K.
  • Corvus Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2309 holding.
  • UBS AM first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.